Efficacy and Safety of Guselkumab, an Interleukin‐23p 19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

RCT (n=739) found that the proportion of patients achieving ACR20 response atweek 24 was maintained up to week 52 for both the 4 weekly and 8 weekly dosing regimens (responses of 71% and 75% respectively by weeks 52). Skin response were also maintained.

SPS commentary:

RCT (n=739) found that the proportion of patients achieving ACR20 response atweek 24 was maintained up to week 52 for both the 4 weekly and 8 weekly dosing regimens (responses of 71% and 75% respectively by weeks 52).  Skin response were also maintained.

Source:

Arthritis & Rheumatology